Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Viking Therapeutics (VKTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Viking Therapeutics's actual EPS was -$0.58, missing the estimate of -$0.46 per share, resulting in a -27.39% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
